NEW YORK – Biolabs International announced Thursday that its exclusive distribution partner, Watmind USA, has obtained Emergency Use Authorizations from the US Food and Drug Administration for over-the-counter and point-of-care antigen tests to detect COVID-19 and influenza infections.
The Watmind USA SpeedySwab Rapid COVID-19 + Flu A&B Antigen Self-Tests are combined nasal tests to detect and distinguish SARS-CoV-2 infection and influenza A and B.
The firm's OTC test has a shelf life of up to 21 months, while the POC test has a shelf life of up to 18 months, Biolabs International said in a statement.
The self-tests are authorized for nonprescription home use with self-collected anterior nasal swab specimens from individuals aged 14 years or older, or with adult-collected anterior nasal swab specimens from individuals 2 years or older.
A Watmind USA test for COVID-19 previously obtained EUA in July 2022.
San Diego-based Biolabs International has now launched the tests in the US through its network of distributors.